English

Bivalirudin Acetate 128270-60-0

98% up by HPLC, Pharma Grade, USP, cGMP, DMF

Contact Now

Product Detail

Product Information

Product name	Bivalirudin Acetate
CAS No.	128270-60-0
Synonyms	BIVALIRUDIN;BIVALIRUDIN TRIFLUOROACETATE;Bivalirudin, TFA;BITTERMELONP.E;Human Bivalirudin;Bivalirudin Acetate;H-D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH;H-D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH trifluoroacetate salt
Molecular Formula	C98H138N24O33
Molecular Weight	2180.29
Quality Standard	98% up by HPLC, USP, cGMP, DMF
Appearance	white to off-white crystalline powder

COA of Bivalirudin

Items	Specifications	Results
Appearance	White or almost white crystalline powder	White powder
Assay (by HPLC)	98%-102%	99.34%
Identification	Positive	Positive
Absorbance(E1cm)	465-495	482.5
Melting point	191^。C - 195^。C	93.5^。C-195^。C
Loss on drying	< 0.5%	0.19%
Specific rotation	+288^。-298^。	290.2^。
Residue on ignition	< 0.10%	0.03%
Related substances	Total related substances < 1.5%	< 1.3%
Related substances	Single related substances < 0.5%	< 0.4%
Residue solvents	< 0.2%	0.10%
Heavy metals	< 20 ppm	< 10 ppm
Conclusion	Meet the specification of enterprise standard

Usage

Function of Bivalirudin

Bivalirudin is a synthetic anticoagulant. It is an analog of naturally occurring hirudin. It is a polypeptide composed of 20 amino acids. It can bind to thrombin with high affinity and specifically inhibit the activity of thrombin. The reaction catalyzed and induced by thrombin. Bivalirudin can not only bind to free thrombin in plasma, but also bind to thrombin linked to blood clots. This binding is reversible and does not require the presence of ATⅢ. Bivalirudin has a strong anticoagulant effect, and has antithrombotic effect on a variety of animal arterial and venous models. Bivalirudin can prolong partial thromboplastin time (APTT), thrombin time (PT) and activated clotting time (ACT).

Bivalirudin is suitable for patients with unstable angina and unstable angina pectoris undergoing PTCA; percutaneous intervention in acute ischemic coronary complications.